Suzhou Jun Kang Medical Technology Co., Ltd. announced that it expects to receive CNY 100 million in funding from Guangdong Biolight Meditech Co., Ltd.
April 07, 2021
Share
Suzhou Jun Kang Medical Technology Co., Ltd. announced that it will receive an equity round of funding on April 8, 2021. The transaction will include participation from returning investor Guangdong Biolight Meditech Co., Ltd. (SZSE:300246). The company will issue shares at an issue price of CNY 1.35 per CNY 1 registered capital. The transaction has been approved by the board of directors in its 14th Meeting of 7th Directorate of the investor and do not need the Shareholders’ Approval.
GUANGDONG BIOLIGHT MEDITECH CO., LTD. is a China-based company principally engaged in the research, development, production and sales of medical monitoring equipment, hemodialysis products and ancillary products. Its medical monitoring equipment includes monitoring equipment, electrocardiograph, pulse oximeters and central monitoring systems. Its hemodialysis products include hemodialysis machines, hemodialyzers, hemodialysis powders/dialysates and perfusion machines. The Company distributes its products in domestic and overseas markets.
Suzhou Jun Kang Medical Technology Co., Ltd. announced that it expects to receive CNY 100 million in funding from Guangdong Biolight Meditech Co., Ltd.
GUANGDONG BIOLIGHT MEDITECH CO., LTD. 
